Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Perspective

NOD2-dependent BCG-induced trained immunity: A way to regulate innate responses to SARS-CoV2?

Dhammika Leshan Wannigama,a,b,c Alain Jacquetd,e

a Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
b Antimicrobial Resistance and Stewardship Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
c School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, Western Australia, Australia
d Center of Excellence in Vaccine Research and Development, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

e Corresponding author at: Center of Excellence in Vaccine Research and Development, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok 10330, Thailand.
E-mail address: alain.j@chula.ac.th (A. Jacquet).

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic has spread rapidly across the world (Zhu et al., 2020). The clinical manifestations of Covid-19 appear to be extensive, encompassing asymptomatic infection, circulatory and renal injury, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure or death and poses a particular risk to people living with preexisting conditions (Zhu et al., 2020). The severity of Covid-19 results from a profound lymphopenia, the downregulation of type I IFN-mediated antiviral defense, as well as an excessive inflammatory response orchestrated by monocytes and macrophages (Merad and Martin, 2020; Vabret et al., 2020). The potent activation of inflammatory monocytes/macrophages leads to a cytokine storm of IL-6, MCP-1, TNFα (Merad and Martin, 2020; Vabret et al., 2020). This uncontrolled release of cytokines was previously reported during severe infections mediated by other pathogenic human coronavirus as SARS-CoV and MERS-CoV, which, contrary to SARS-CoV2, also triggered high levels of IL-1β (Merad and Martin, 2020; Perlman and Dandekar, 2005).

The early innate immune evasion strategies used by SARS-CoV2 to circumvent type I signaling in order to gain a window of opportunity for virus propagation, remains to be elucidated. SARS-CoV2 could express some immune evasion proteins capable of reducing the interferon regulatory factor 3 (IRF3) and IRF7 activation to limit the type I IFN stimulation (Figure 1), as previously observed for SARS-CoV, and MERS-CoV. (Merad and Martin, 2020; Perlman and Dandekar, 2005; Schäfer and Baric, 2017; Schulz and Mossman, 2016; Vabret et al., 2020). In addition, the epigenetic control of type I IFN innate immune response by SARS-CoV2 could be hypothesized, as MERS-CoV infection mediates repressive histone modification in promoter regions of interferon stimulating genes (ISG) for the shutdown of innate immune signaling (Figure 1) (Merad and Martin, 2020; Perlman and Dandekar, 2005; Schäfer and Baric, 2017; Vabret et al., 2020). Moreover, the kinetics of the systemic and the local IFN responses, an important parameter that determines SARS-CoV2 infection outcomes, needs clinical and experimental clarification. Variations in severity of infection and mortality by SARS-CoV2 are broadly reported worldwide but remain unexplained up to now. One hypothesis associated Covid-19 incidence and mortality with Bacille Calmette-Guérin (BCG) vaccinations (Miller et al., 2020; O’Neill and Netea, 2020). Countries maintaining long-standing universal BCG vaccination policies, such as South Korea and Japan, showed lower SARS-CoV2-associated fatalities than nations such as Italy or USA, which interrupted global BCG vaccination campaigns (Miller et al., 2020). BCG, a live attenuated vaccine against tuberculosis (TB), is nowadays one of the most widely used vaccines globally, covering more than 90% of newborns and infants. Recent epidemiological and clinical findings suggested that, in addition to TB-specific protection, BCG vaccinations trigger as well non-specific effects through the ability to enhance immune protection against other pathogens (Aaby and Benn, 2012; Aaby et al., 2011; Anderson et al., 2012; Colditz et al., 1995; Stensballe et al., 2005). Notably, randomized trials revealed that BCG vaccinations of infants could reduce the risk of lethal respiratory infections by 50% and these protective effects were clearly not related only to tuberculosis prevention (Aaby and Benn, 2012; Aaby et al., 2011). Protective effects of BCG- was evidenced for a wide range of pathogens, including Staphylococcus aureus, Candida albicans, and Yellow fever virus (Covílán et al., 2019; Moorlag et al., 2019). Also, mice vaccinated with BCG reduced influenza A
NOD2-dependent BCG-induced trained immunity may be determinant for the control of SARS-CoV2 infection. SARS-CoV2 could adopt different strategies (immune evasion protein expression and epigenetic changes) to delay or fully inhibit host type I interferon (IFN) antiviral defenses, resulting in the development of pulmonary hyper-inflammation in severe Covid-19. We suggest that NOD2 signaling following BCG vaccinations could trigger epigenetic reprogramming of innate immune responses in macrophages/monocytes to prevent the cytokine storm. Abbreviation; CCL2, CC chemokine ligand 2, IRF, interferon regulatory factors, NOD2, nucleotide-binding oligomerization domain-containing protein 2, NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells, MAVS, mitochondrial antiviral-signaling protein, PRR, pattern recognition receptor, TRAF, tumor necrosis factor receptor (TNFR)-associated factor, TBK1, serine/threonine-protein kinase 1, TRF3, telomere binding protein 3.

Although the mechanisms of these BCG-induced immunomodulatory effects remain to be fully elucidated, induction of innate immune memory appeared to be the most plausible explanation (Aaby and Benn, 2012). This T- and B-cell independent trained immunity results from epigenetic reprogramming of innate immune cells, specifically through histone modifications and leading to upregulation of proinflammatory cytokine production (IL-1, IL-6, TNFα) (Figure 1) (Covián et al., 2019; Kleinnijenhuis et al., 2012; Moorlag et al., 2019). Notably, BCG vaccinations were shown to trigger H3K4me3 variation in human peripheral blood monocytes (Covián et al., 2019; Kleinnijenhuis et al., 2014; Kleinnijenhuis et al., 2012; Moorlag et al., 2019). The epigenetic control of proinflammatory cytokine gene expression by BCG is mainly dependent on the nucleotide-binding oligomerization domain 2 receptor (NOD2) signaling in monocytes (Covián et al., 2019; Kleinnijenhuis et al., 2012) as evidenced by the following data: (1) ablation of TLR2, TLR4 or Dectin-1 signaling did not abolish cross-protection induced by BCG (Kleinnijenhuis et al., 2012); (2) homozygous 1022insC frameshift mutation leading to complete NOD2 deficiency, abolished BCG-induced cytokine upregulation in human monocytes (Kleinnijenhuis et al., 2012); (3) The training effects elicited by BCG could be reproduced with NOD2 agonist muramyl dipeptide (MDP) from the mycobacterial cell wall (Covián et al., 2019; Kleinnijenhuis et al., 2012). Of note, these epigenetic modifications were shown to increase NOD2 expression (Figure 1). Virulent Mycobacterium tuberculosis strains induce expression of type I IFN mediated by NOD2 together with cyclic GMP-AMP synthase (cGAS) signaling (Moreira-Teixeira et al., 2018). Such type I IFN responses were shown to downregulate proinflammatory cytokines and impaired antibacterial Th1 responses (Moreira-Teixeira et al., 2018). Interestingly, BCG is capable of eliciting type I IFN expression in both human and mouse primary macrophages, albeit to a significantly lesser degree than pathogenic M. tuberculosis (Moreira-Teixeira et al., 2018).

Based on these data, we speculate that BCG-trained innate immunity could similarly control SARS-CoV2 infection by appropriate control of type I IFN and proinflammatory cytokine responses (Figure 2). According to the critical role of NOD2 in BCG-induced innate memory, we hypothesize that NOD2 signaling in macrophages/monocytes could be determinant to tune innate immune responses against SARS-CoV2 (Figure 1).

The role of NOD2 signaling in SARS-CoV2 infection remains altogether unknown up to now. However, NOD2 was reported to sense ssRNA from viruses as Respiratory Syncytial Virus (RSV), Vesicular Stomatitis Virus (VSV), ParaInfluenza, Influenza A, or Foot-and-mouth disease virus (FMDV) to stimulate type I IFNs responses through the mitochondrial membrane-anchored CARD protein (MAVS)/I/RF3/IRF7 signaling (Keestra-Gounder and Tsolis,
2017; Moreira and Zamboni, 2012; Sabbah et al., 2009). Interestingly, MERS-CoV is capable of decreasing NOD2 expression in macrophages (Kim et al., 2019).

We thus propose that BCG vaccinations, through the induction of NOD2-dependent epigenetic reprogramming, inhibit SARS-CoV2 evasion strategies and prevent excessive accumulation of monocytes, macrophages, and neutrophils in the lungs and consequently the cytokine storm induction (Figure 1). Particularly, BCG could early elicit type I IFN expression by NOD2 signaling (Figure 2). This early antiviral response would be critical for the control of SARS-CoV2 propagation as delayed IFN-I production is associated with the pathology of Covid-19 (Acharya et al., 2020; Schulz and Mossman, 2016) (Figure 2). The in-depth characterization of the molecular crosstalk between type-I IFN and proinflammatory cytokine signaling together with epigenetic changes associated with SARS-CoV2 infection will be decisive to clearly measure the potential of BCG-trained innate memory for the control of Covid-19. Results from large clinical trials (ClinicalTrials.gov identifiers NCT04328441 and NCT04327206) currently under way will be influential in recommending BCG vaccinations to prevent Covid-19. Together with the extensive characterization of innate immune activation by SARS-CoV2, several key unanswered research questions need to be addressed: What is the role of NOD2 in SARS-CoV2 infection? Could BCG-induced trained immunity positively influence NOD2 signaling for the early induction of IFN-I inflammatory responses? What are the epigenetic changes triggered by SARS-CoV2 in innate immune cells? Could the epigenetic reprogramming by BCG vaccinations interfere with epigenetic changes modulated by SARS-CoV2? Is BCG-trained immunity in the context of Covid-19 dependent on the type of BCG vaccine strains? As Covid-19 progresses to severe disease, particularly in elderly patients, is the strength of BCG-induced memory age-dependent?

BCG represents an elegant platform as well for the development of recombinant vaccines, including auto-adjuvant capacities (Covián et al., 2019). Consequently, vaccine candidates based on recombinant BCG expressing SARS-CoV2 antigens could simultaneously drive potent innate immune memory and adaptive responses. Finally, NOD2 synthetic ligands could be selected for the control of the innate immune response during SARS-CoV2 infection and could also be used as vaccine adjuvants. Together with the development of vaccine(s) against Covid-19, we believe that NOD2-dependent BCG-induced trained immunity will strengthen antiviral defenses to prevent any future episode of coronavirus pandemics.

Innate immunity, acting as the first element of defense, can represent, together with other mechanisms, a promising target for the treatment of patients or at least to better understand the pathogenesis of the disease.

**Authors’ contributions**

The authors contributed equally to all aspects of the article.

**Competing interest**

The authors declare no competing interests.

**Acknowledgments**

Dhammika Leshan Wannigama was supported by Chulalongkorn University (Second Century Fund- C2F Fellowship), and the University of Western Australia (Overseas Research Experience Fellowship). Alain Jacquet was supported by the Rachadapisek Sompotch Fund, Faculty of Medicine, Chulalongkorn University (RA61/123), and Chulalongkorn Academic Advancement (2nd Century Project-CUAASC).

**References**

Aaby P, Benn CS. Saving lives by training innate immunity with Bacille Calmette-Guérin vaccine. Proc Natl Acad Sci U S A 2012;109(43):17317–8.

Aaby P, Roth A, Ravin H, Napirna BM, Rodrigues A, Lisse IM, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial non-specific effects in the neonatal period. J Infect Dis 2011;204(2):245–52.

Acharya D, Liu G, Gack MJ. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol 2020;20(7):397–8.

Anderson EJ, Webb EL, Mawsa PA, Kizza M, Lyadda N, Nampjia M, et al. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 2012;30(12):2083–9.

Colditz GA, Berkley KS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of Bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995;96(1 Pt 1):29–35.

Covin C, Fernández-Fierro A, Betamal-Díaz A, Díaz FE, Vasquez AE, Lay MK, et al. BCG-induced cross-protection and development of trained immunity: implications for vaccine design. Front Immunol 2019;10:2806.

Keestra-Gounder AM, Tolsis RM. NOD1 and NOD2: beyond peptidoglycan sensing. Trends Immunol 2017;38(10):758–67.

Kim J, Yang YJ, Jang YS. Human j-defensin 2 is involved in CCR2-mediated Nod2 signal transduction, leading to activation of the innate immune response in macrophages. Immunobiology 2019;224(4):502–10.

Kleinijenhuis J, Quintijn J, Preiers F, Benn C, Joosten LA, Jacobs C, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 2014;6(2):152–2.

Kleinijenhuis J, Quintijn J, Preiers F, Joosten LA, Hirm DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent non-specific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012;109(43):17537–42.

Mered M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020;20(6):355–62.

Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020;2020.03.24.20042937.

Moorlag S, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect 2019;25(12):1473–8.

Moreira LO, Zamboni DS, NOD1 and NOD2 signaling in infection and inflammation. Front Immunol 2012;3:328.

Moreira-Texeira L, Mayer-Barber L, Sher A, O’Garra A. Type I interferons in tuberculostasis: foe and occasionally friend. J Exp Med 2018;215(5):1273–85.

O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol 2020;20(6):335–7.

Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 2005;5(12):917–27.

Sabbah A, Chang TH, Harnack R, Frohlich V, Tominga K, Dubé PH, et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009;10(10):1073–80.

Schäfer A, Baric RS. Epigenetic landscape during coronavirus infection. Pathogens 2017;6(1).
Schulz KS, Mossman KL. Viral evasion strategies in type I IFN signaling — a summary of recent developments. Front Immunol 2016;7:498.

Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine 2005;23(10):1251–7.

Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: current state of the science. Immunity 2020;52(6):910–41.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–33.